WO1999037764A2 - New members of the glypican gene family - Google Patents
New members of the glypican gene family Download PDFInfo
- Publication number
- WO1999037764A2 WO1999037764A2 PCT/EP1999/000329 EP9900329W WO9937764A2 WO 1999037764 A2 WO1999037764 A2 WO 1999037764A2 EP 9900329 W EP9900329 W EP 9900329W WO 9937764 A2 WO9937764 A2 WO 9937764A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- glypican
- nucleotide sequence
- sequence
- probes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4725—Proteoglycans, e.g. aggreccan
Definitions
- the present invention relates to the characterization and chromosomal localization of new members of the glypican gene family and to the use of members of this family in diagnostics and/or therapeutics.
- Glypicans are glypiated cell surface heparan sulfate proteoglycans, the first of which was originally identified in human lung fibroblasts (David et al . , 1990) .
- the known five members of this family have similar core protein sizes (about 60 kDa) , share a unique and very conserved cysteine spacing, and are linked to the cell membrane by a glycosyl phosphatidyl inositol (GPI)- anchor.
- GPI glycosyl phosphatidyl inositol
- Those five known glypicans are of vertebrate origin and include glypican (glypican-1, David et al . , supra), Cerebroglycan (glypican-2, Stipp et al .
- All the structural features of the vertebrate glypicans are also present in the product of dally (division abnormally delayed) , a locus identified in Drosophila melanogaster by genetic screening for mutants affecting cell division patterning in the developing central nervous system (Nakato et al . , 1995). Besides disturbing cell cycling in the nervous system dally mutations also affect viability and produce morphological defects in several adult tissues, including the eyes, antennae, wings and genitalia.
- the dally mutants the well established co-receptor activities of the cell surface proteoglycans for various ligands that are known to mediate developmental instructions, and the tissue and stage-specific expressions of the glypicans, all implicate the glypican group of integral membrane proteoglycans in the control of cell division and patterning during development.
- This contention has recently been corroborated by the identification of mutations in GPC3 , the gene coding for the human homologue of OCI-5 (glypican-3 ) , that cause the Simpson- Golabi-Behmel overgrowth syndrome (SGBS) (Pilia et al . , 1996) .
- SGBS Simpson- Golabi-Behmel overgrowth syndrome
- This X-linked condition which clinically has to be differentiated from the autosomal Beckwith-Wiedeman Syndrome, is characterized by pre- and post-natal overgrowth with visceral and skeletal anomalies, and is associated with a high risk for developing embryonal tumors, including Wilms ' tumor and neuroblastoma .
- chromosomal assignment of the genes for the members of the glypican family and the identification of potentially additional members in this family may be of general relevance for the understanding of somatic overgrowth and tumor predisposition.
- glypican the homologue of OCI-5 (glypican-3) and glypican- 5 have been identified in human.
- the corresponding genes GPC1 , GPC3 and GPC5 have been localized to chromosomes 2q35-q37, Xq26 and 13q32, respectively (Vermeesch et al . , 1995; Pilia et al . , 1996; Veugelers et al . , 1997) .
- the cDNA nucleotide and derived amino acid sequences of these genes are given in figures 3, 4 and 5, respectively.
- the object of the present invention to provide new members of the glypican family, and to study their possible implications in various medical indications. It is a further object of the invention to use the information derivable from the members of the glypican gene family for designing diagnostic methods and kits and/or for the development of therapeutics.
- two novel human cDNAs were identified encoding glypican-related proteins. The corresponding gene for the first was mapped to chromosome 13q32. In this application this gene will be identified as GPC6, whereas the protein encoded by the gene will be called glypican-6.
- the predicted primary structure of the GPC6 protein was found to show significant sequence similarity to glypican (glypican- 1) , to the human homologue of OCI-5 (glypican-3) , to glypican-5, to the glypican-related proteins Cerebroglycan (glypican-2 of the rat) , to K-glypican (glypican-4 of the mouse) and to the gene product of the dally locus in Drosophila melanogaster .
- the similarity pertains to a conserved sequence motif, present in all seven proteins and that include a set of 14 conserved cysteine residues found in specific positions.
- Glypican-6 is, however, more similar to K- glypican and human glypican-4 (see below) than to the other glypicans.
- glypican- 6 is more similar to glypican-1 and glypican-2 than to glypican-3 and glypican-5.
- the gene encoding glypican-6 (GPC6) has a similar exon-intron organization as the gene encoding glypican-4 (GPC4 as was now found according to the invention) and the gene encoding glypican-1 (GPCl) .
- This organization differs from the exon-intron organization of the gene encoding glypican-3 (GPC3) and that of the gene encoding glypican-5 (GPC5) , while GPC3 and GPC5, in turn, resemble one another in terms of their intron-exon organizations.
- GPC3 and GPC5 in turn, resemble one another in terms of their intron-exon organizations.
- a cDNA is provided that encodes the human homologue of K- glypican (glypican-4) , the corresponding gene of which localizes to chromosome Xq26 in very close proximity to the gene for glypican-3.
- the GPC3 and GPC4 genes are adjacent, or near adjacent, to one another on chromosome Xq26, while the GPC5 and GPC6 genes are adjacent, or near adjacent, to one another on chromosome 13q32.
- a member (GPC3, respectively GPC5) of one of the glypican subfamilies is physically linked to a member (GPC4, respectively GPC6) of another glypican subfamily. This indicates that the glypican subfamilies and various members of these families may have arisen from the duplications of one ancestral glypican gene and ancestral gene cluster. Maintenance of the physical associations between these genes during evolution suggests that these genes may also be functionally linked.
- GPC3 the gene for glypican-3
- GPC4 the gene for glypican-4
- various diagnostic tests could be developed in order to detect aberrations in the genes that encode glypicans and aberrations in the expression levels of these genes.
- this knowledge can be used to develop therapeutic compounds that restore the physical damage caused by the mutant gene .
- the aberrations in the gene comprise for example deletions or translocations within either or both of the two genes, but also mutations in either or both of them. These aberrations may lead to the absence of gene products or to abnormal gene products. Thus, the expression level of the gene may be used as another parameter indicating the presence of one or more aberrant genes .
- GPC3 and GPC4 can be extrapolated to other members of the glypican gene family.
- GPC5 and GPC6 are likewise associated. Aberrations in these genes can be identified in a similar manner as herein described for GPC3 and GPC4.
- SSCP single strand conformation polymorphism
- RFLP restriction fragment length polymorphism
- gel electrophoresis Southern blot analysis
- PCR DNA sequencing
- Diagnostic methods according to the invention are based on the information derivable from the gene and/or its gene product.
- Such information comprises the nucleotide sequence, either sense or antisense, of the gene and the complementary strand thereof, and the amino acid sequence of the gene product encoded by the coding sequence of the gene.
- the information derivable from the gene or gene product can very well be defined by a person skilled in the art by referring to figures 1 to 6.
- Figures 1 to 5 disclose the nucleotide sequence of the human cDNAs for glypicans 1 and 3 to 6, as well as the derived amino acid sequence of the protein encoded by the cDNA.
- Figure 6 gives an alignment of the predicted amino acid sequences and the position of the exon boundaries for each of them. This information can be used to define so-called derivatives.
- Derivatives of the nucleotide sequence of the gene are the gene itself, either isolated or synthetic, fragments of the gene, either isolated or synthetic and having a length that is smaller than the complete gene; primers, comprising at least 10 consecutive gene specific nucleotides, preferably about 20 gene specific consecutive nucleotides of the nucleotide sequence of the gene; longer oligonucleotides up to the full length of the sequence of the gene; antisense variants of the gene, the fragments or the primers; antibodies directed to the gene, fragments, primers or complementary strands thereof; any specific ligand for DNA that can be used as a specific probe, peptide nucleic acid probes.
- transcripts mRNA sequences of the gene, from which in turn cDNA, antisense RNA, antisense cDNA, antibodies directed to the transcript, sense and antisense cDNA, antisense RNA and any specific ligand for RNA that can be used as a specific probe can be derived.
- Derivatives of the amino acid sequence include the isolated or synthetic gene product (also called protein or polypeptide); isolated or synthetic peptides, comprising a specific sequence of consecutive amino acids encoded by the gene, antibodies directed to the gene product or peptides and any specific ligand for peptides that can be used as a specific probe.
- Other derivatives are heparan sulfate chains or heparan sulfate structures, antibodies directed to heparan sulfate structures present on the product of the natural or synthetic gene as a result of the posttranslational modification of these gene products, any specific ligand for heparan sulfate that can be used as a specific probe.
- the gene or cDNA may be used for the transfection of cells, which transfection results in cells expressing or secreting the desired glypican.
- the transfected cells can be used to produce transgenic animals therefrom, which in case the gene is an aberrant gene, can be used to study the effect of the aberration or to test medicaments.
- natural glypicans may be isolated or recombinant (wild type or mutated) glypicans produced (in transfected cells or transgenic animals) for use as therapeuticals .
- Such therapeuticals may be used to mimic the biological effects of the glypicans (control of cell growth and differentiation) , in attempts to remedy the effects of absolute or relative deficiencies of these genes or to enhance the effects of the normal genes.
- therapeuticals based on modified glypican gene sequences may also be used to block the effects of the glypicans, in attempts to remedy the effects of absolute or relative overexpressions or activities of the products of the various glypican genes.
- recombinant soluble glypicans may be used as decoy receptors for antagonizing the effects of factors that depend on membrane-anchored glypicans, whereas the delivery of membrane- intercalatable glypicans to cells may restore cellular sensitivity to these factors. Diagnostic methods according to the invention comprise but are not limited to the following.
- a method for diagnosing aberrations in a glypican encoding gene comprises isolation of the gene from cells expected to be harboring an aberrant gene; and comparison of the nucleotide sequence of the gene thus obtained with the nucleotide sequence of a wild type gene.
- wild type gene as used in this application is intended to encompass a gene from a non- affected individual.
- sequences given in figures 1 to 5 are representatives for wild type gene sequences.
- Comparison between the potentially aberrant and wild type nucleotide sequences can be performed at various levels. On a first level it can be established whether the expected aberration (s) has (have) resulted in restriction fragment length polymorphism. In order to do this the isolated gene and a wild type comparison gene are separately digested with one or more selected restriction enzymes. The digest thus obtained is separated on a gel revealing a pattern of bands. Differences in the pattern indicate the presence of differences in the restriction sites present in the polynucleotide and thus changes in the sequence thereof. Deletions can be detected by means of any nucleic acid amplification technique such as the Polymerase Chain Reaction (PCR) . For this, probes are identified corresponding to various parts of the gene to be diagnosed, for example exons. Amplification between a set of probes will only occur if the part of the gene to which a selected set of probes should hybridize is still present. In addition or as an alternative the length of the amplified fragment indicates whether any part is deleted.
- PCR Polyme
- Point mutations can be identified by more sophisticated techniques such as SSCP (single-strand conformation polymorphism screening) , heteroduplex analyses, DNA-chips, chemical and enzymatic methods, sequencing of PCR products, denaturant gradient gel electrophoresis or other state of the art methods that may become available in the future.
- SSCP single-strand conformation polymorphism screening
- heteroduplex analyses DNA-chips
- chemical and enzymatic methods sequencing of PCR products
- denaturant gradient gel electrophoresis denaturant gradient gel electrophoresis or other state of the art methods that may become available in the future.
- Translocations can be detected by hybridizing a set of chromosomes with a first probe that hybridizes to a part of the glypican gene that is not likely to be involved in the translocation, inversion or deletion and a second probe that hybridizes to a part of the glypican gene that is likely to be involved in such aberration. When a translocation has occurred the second probe will be found on another chromosome than the first one. If the probable translocation partner is identified, an additional set of probes can be used which hybridize to the translocated part and the remaining part, respectively of the translocation partner and bearing a different label from the first set of probes. Upon translocation one of the probes of the first set will be found on the chromosome of the translocation partner and one probe of the second set will be found on the chromosome of the glypican gene and vice versa.
- Identifying inversions and deletions works in a similar way with two probes, one that hybridizes to a part of the gene that is not likely to be involved in the inversion or deletion and a second probe that is likely to be involved in such aberration.
- the second probe will be found closer to or further away from the first probe than in a non-aberrant chromosome.
- deletions one of the probes will be missing on the aberrant chromosome.
- Diagnosis can also be performed at the level of the (potentially absent or aberrant) protein encoded by the glypican gene.
- Antibodies directed to the gene product or protein can be used on Western blots to detect the presence of the protein in the cell or to assess the amount of protein present .
- the diagnostic tests of the invention can be performed on various source materials.
- RF P, deletion PCR, SSCP and chromosome analyses are for example performed on blood cells or tissue biopsy samples of the patient and his or her family. Furthermore, tumor cells and normal cells of these subjects may be used. For protein analysis, tissue samples, sera, tissue fluids of patients and family, pleura exudates, ascites etc. may be used.
- Figure 1 shows the nucleotide sequence of the glypican-6 cDNA, comprising the coding sequence of the newly identified GPC6 gene, and the predicted amino acid sequence .
- Figure 2 shows the nucleotide sequence of the glypican-4 cDNA, comprising the coding sequence of the GPC4 gene, and the predicted amino acid sequence.
- Figure 3 shows the nucleotide sequence of the human glypican-1 cDNA, comprising the coding sequence of the GPC1 gene, and the predicted amino acid sequence (Genbank accession number X54232; David et al . , J. Cell Biol. Ill, 3165-3176, 1990) .
- Figure 4 shows the nucleotide sequence of the human glypican-3 cDNA, comprising the coding sequence of the GPC3 gene, and the predicted amino acid sequence (Genbank accession number Z37987) .
- Figure 5 shows the nucleotide sequence of the human glypican-5 cDNA, comprising the coding sequence of the GPC5 gene, and the predicted amino acid sequence (Genbank accession number U66033; Veugelers et al . Genomics 40, 24-30, 1997) .
- Figure 6 shows the alignment of the predicted amino acid sequences of the members of the glypican family.
- GPC1 is human glypican (David et al . , 1990)
- GPC3 is the translated ORF of MXR7 (GenBank #Z37987) and the human homologue of rat OCI-5
- GPC4 is human glypican-4 (see example 2) and the human homologue of K-glypican (Watanabe et al . , 1995)
- GPC5 is human glypican-5 (Veugelers et al . , 1997) .
- the set of fourteen conserved cysteines and the putative glycosaminoglycan attachment sites are outlined by underlining.
- Figure 7A shows a Northern blot for GPC6 of human fetal Brain (lane 1), Lung (lane 2), liver (lane 3) and Kidney (lane 4) RNA.
- the positions of RNA size markers (kb) are indicated in the abscissa.
- Figure 7B shows a Northern blot for GPC6 of human adult Heart (lane 1) , Brain (lane 2) , Placenta
- FIG. 7C shows a Northern blot for GPC6 of human adult Spleen (lane 1) , Thymus (lane 2) , Prostate (lane 3) , Testis (lane 4) , Ovary (lane 5) , Small Intestine (lane 6) , Colon Mucosal lining (lane 7) , and Peripheral Blood Leukocyte (lane 8) RNA.
- the positions of RNA size markers (kb) are indicated in the abscissa.
- Figure 8 shows heparan sulfate core protein expression in control and GPC-transfectant Namalwa cells.
- This antibody reacts with the desaturated uronates that are generated by heparitinase and that remain in association with the core protein after the enzyme treatment and during electrophoresis.
- heparitinase After heparitinase it therefore detects all heparan sulfate proteoglycan core proteins present in the sample. The positions of protein size markers are indicated in the abscissa.
- Hase heparitinase; Case: chondroitinase ABC.
- Control wild type Namalwa cells (wt) and Namalwa cells, transfected with pREP4 0; GPC1, GPC4 and GPC6 : Namalwa cells, transfected with respectively the plasmids glypl-pREP4, glyp4-pREP4 and glyp6-pREP4.
- Figure 9 shows heparan sulfate expression in control and GPC-transfectant Namalwa cells. FACS analysis of non-digested and heparitinase-digested cells, using the native HS-specific 10E4 antibody (non digested cells (- • - • -)) and delta-HS-specific 3G10 antibody (digested cells ( ).
- Namalwa cells transfected with pREP4; GPC1 , GPC3, GPC4 , GPC5 and GPC6 : Namalwa cells, transfected with respectively the plasmids glypl-pREP4, glyp3-pREP4, glyp4-pREP4, glyp5-pREP4 and glyp6-pREP4.
- Figure 10 shows the chromosomal localization of GPC6 to chromosome band 13Q32 as a photo (A) and a schematic representation thereof (B) . Arrows indicate colored bands .
- Figure 11A shows the Northern blot for GPC4 of human fetal Kidney (lane 1) , Liver (lane 2) , Lung (lane 3) and Brain (lane 4) RNA.
- the upper part of the figures represents the hybridization with the GPC4 probe; the lower part the hybridization with a ⁇ -actin control probe .
- Figure 11B shows the Northern blot for GPC4 of human adult Heart (lane 1) , Brain (lane 2) , Placenta (lane 3), Lung (lane 4), Liver (lane 5), Skeletal Muscle (lane 6) , Kidney (lane 7) and Pancreas (lane 8) RNA.
- FIG 11C shows the Northern blot for GPC4 of human adult Spleen (lane 1), Thymus (lane 2), Prostate (lane 3) , Testis (lane 4) , Ovary (lane 5) , Small intestine (lane 6) , Colon; mucosal lining (lane 7) , peripheral blood leukocyte (lane 8) .
- the positions of RNA size markers (kb) are indicated in the abscissa.
- Figure 12A illustrates the chromosomal localization of GPC4 to chromosome Xq26 and relative order of GPC3 and GPC4.
- FISH FISH was performed using either BAC 35H9 or BAC 68G14 on metaphase spreads, prepared from PHA-stimulated normal peripheral blood leukocytes ( Figure 12A) .
- FISH was performed with BAC ' s for GPC4 (35H9, 68G14 labeled in red) and BAC ' s for GPC3 (166D10 and 36D20, labeled in green) on PHA-stimulated cell lines GM3884, GM13034 and GM0097 ( Figures 12B, 12C and 12D) .
- Chromosomes were counterstained with DAPI, and the images were taken using a cooled CCD device. Arrows indicate the positive signals at chromosome Xq26.
- Figure 13A and 13B show a BAC/PAC contig linking GPC4 to GPC3 on Xq26.
- Figure 13C shows glypican deletions found in SGBS-patients . STS ' s are indicated by black circles; exons are indicated by grey squares. Not drawn to scale (The distance between SWXD1698 and exon-8 of GPC3 is approximately 250 kb (See Pilia et al . , 1996) .
- Table 1 shows the primers used in 5 ' -RACE experiments for the identification of GPC6.
- Table 2 shows the percentages of amino acid identities between glypicans.
- Table 3 shows the primers used in the RACE experiments with GPC4.
- Table 4 shows the gene specific primers used for sequencing of the GPC4 gene.
- Table 5 shows the novel STSs MV1 , MV2 and MV3.
- Table 6 shows localization of FISH signals in
- Table 7 shows the intron-exon organization of GPC4.
- Table 8 shows primers to be used in deletion analysis of GPC3 and GPC4.
- Table 9 shows the primers for use in SSCA of GPC4.
- Table 10 shows the results of deletion and SSCP screening in 8 patients with SGBS.
- Table 11 shows primer pairs for deletion PCR of
- Table 12 shows primer pairs for deletion PCR of GPC6.
- the isolation of one of the cDNAs of the present invention started from EST database entries showing significant similarity with (cDNA coding for) glypicans.
- the cDNA was found in a cDNA library of fetal brain.
- EST entries (including homology data) were retrieved from dbEST using a text string based query interface (http://www.ncbi.nlm.nih.gov/dbEST/index.html). Protein alignments were made using the program Clustal . DNA alignments were made using the program GENEPRO .
- the primer sets used for the 5 ' -RACEs (5' rapid amplification of cDNA ends) are given in Table 1.
- the cDNAs were amplified from a library of adaptor-ligated double strand human fetal brain cDNA (Clontech, Palo Alto, CA) through a two-step PCR protocol. In the first PCR a gene-specific primer was used and an anchor primer provided by the supplier. Then 1 ⁇ l of each first PCR was used as template for a second PCR, using a second gene-specific nested primer (cf .
- Clone zh83a06 from the Soares fetal liver/spleen library (Lennon et al . , 1996), which had yielded EST No. AA001322, was obtained from the I.M.A.G.E. Consortium (http://www-bio.llnl.gov/bbrp/image/image.html) through Research Genetics, Inc. (Huntsville, AL) . This clone (ID: 427858) was completely sequenced, yielding residues 1835- 2748 of the composite cDNA sequence that is shown in figure 1.
- Metaphase spreads were prepared from PHA- stimulated human peripheral blood lymphocytes cultured for 72 hours. Prior to FISH, slides were treated with RNAse A and pepsin as described (Wiegant et al . , 1991) . Human Cotl DNA (Life Technologies) was used as a competitor. Denaturation of the slides and probes, hybridization, and subsequent cytochemical detection of the hybridization signals were performed as previously described (Vermeesch et al . , 1995) . Chromosomes were counterstained with DAPI and the slides were mounted in Vectashield mounting medium (Vector Laboratories Inc, Burlingame, CA) . The signal was visualized by digital imaging microscopy using a cooled charge-coupled device camera (Photometries Ltd, Arlington, AZ) . Merging and pseudocoloring were performed using the Smart Capture software (Vysis, Stuttgart, Germany).
- the membranes for the Northern blots were obtained from Clontech. Hybridization was performed for two hours at 68 °C, using Expresshyb solution (Clontech) according to the manufacturer's specifications.
- the probe was either a 32 P-oligolabeled BamHI-Xbal fragment from the I .M.A.G.E. -clone 427858 (corresponding to residues 2147- 2488 of the GPC6 sequence) or a Hindlll-BamHI fragment from the GPC6 composite cDNA sequence (corresponding to residues 1724-2147 of the GPC6 sequence) .
- Dehybridisation included two washes with 2.0% SSC, 0.05% SDS (5 min at RT; 30 min at 60°C) and a high stringency wash with 0.1% SSC, 0.1% SDS (30 min at 65°C) .
- Notl-BstEII and BstEII-Aval fragments from overlapping RACE-clones, and the Aval -HindiII fragment of I .M.A.G.E. -clone 427858 were ligated together in pCR2.1.
- Notl-Xbal and Xhol-Xbal fragments from this construct, containing the Kozak sequence and initiator ATG, the full coding sequence and the stop codon, were subcloned in, respectively, pcDNAIII and pBluescript .
- the full length cDNA was released from pBluescript with Kpnl and Notl, and ligated into pREP4 , yielding the plasmid glyp6-pREP4.
- Namalwa cells (ATCC CRL 1432) were routinely grown in DMEF12 medium supplemented with 10% FCS and L- glutamine. For transfection, the cells were prewashed with Ca- and Mg-free PBS and incubated for 10 min at 4°C (10 7 cells in 1 ml Ca/Mg free PBS) with 30 ⁇ g glyp6-pREP4 plasmid before electroporation at 240 V and 960 ⁇ F (Gene Pulser, Biorad) .
- Figure 1 represents the merged sequences of these clones, and the predicted structure of the protein encoded by the message that corresponds to this cDNA.
- the sequence features an ATG start codon, in a Kozak sequence context, at position 586 and a TAA stop codon at position 2251.
- Two AATAAA sequences are present at positions 2598 and 2690.
- the open reading frame in the sequence codes for a protein of 555 residues.
- the protein sequence starts and terminates with hydrophobic signal peptide-like sequences. It contains no asparagines that correspond to potential N-glycosylation sites, and contains four serine-glycine dipeptide sequences.
- Ser-Gly dipeptide sequences occur towards the C-terminus of the protein, and form part of a direct Ser-Gly repeat sequence.
- This Ser-Gly tetra-repeat sequence is flanked, both upstream and downstream, by acidic amino acids (D/E) , reproducing a motif that has been reported to promote the assembly of heparan sulfate in proteoglycans.
- the downstream acidic residues occur within the sequence CMDDVC, and may reproduce a motif (a small acidic loop supported by a disulfide bond) that is shared by most glypicans (except glypican-2) .
- This loop follows the SG repeats in the glypicans 1, 4 and 6, but interrupts or precedes the SG repeats in the glypicans 3 and 5.
- Alignment of this predicted protein sequence with the protein sequences of the other known members of the glypican family revealed significant sequence similarities (figure 6) .
- This similarity included the 14 cysteines and the position and identity of several additional amino acid residues that are conserved in all glypicans identified so far.
- the entire protein showed 63% of sequence identity to human glypican-4, 44% of identity to human glypican-1, and 24-25% identity to the human glypicans 3 and 5.
- glypican family of cell surface heparan sulfate proteoglycans may be composed of discrete subfamilies: one comprising glypicans 4 and 6, and possibly also glypican-1 (and 2); the second comprising glypicans 3 and 5.
- the message is expressed at very high levels in ovary, and at high levels in liver, kidney, small intestine and colon (mucosal lining) .
- the message is also present at low levels in heart, brain, placenta, lung, skeletal muscle, pancreas, spleen, thymus, prostate and testis (figures 7B and C) .
- the message is undetectable in peripheral blood leukocytes.
- In adult kidney the probes also detected a second less abundant message of approximately 5.8 kb.
- Adult heart and adult skeletal muscle yielded an extra band of -3.9 kb .
- the glypican-6 insert was subcloned in the pREP4 episomal expression vector and transfected in Namalwa cells.
- the Namalwa cells used for these experiments had previously been shown to express little endogenous heparan sulfate, but to support the synthesis of large amounts of heparan sulfate when transfected with cDNAs (cloned in pREP4) that code for syndecans or glypican-1.
- GPC6 Two BACs for GPC6, 114A17 and 182F5 were used to localize GPC6 to chromosome band 13q32 by fluorescent in situ hybridization on metaphase chromosomes (figure 10; BAC 114A17) . From this it follows that GPC5 (closely related to GPC3) and GPC6 (closely related to GPC4) map in close proximity of one another on 13q32, mimicking the clustering of the GPC3 and GPC4 genes on chromosome Xq26 (see example 2) .
- GPC5 closely related to GPC3
- GPC6 closely related to GPC4 map in close proximity of one another on 13q32, mimicking the clustering of the GPC3 and GPC4 genes on chromosome Xq26 (see example 2) .
- the isolation of the cDNA that is used in the present invention for diagnostics started from a partial cDNA for human glypican-4.
- a cDNA comprising the complete coding sequences for human glypican-4 was found in a cDNA library of fetal brain.
- EST entries were retrieved from dbEST using either a text string based query interface (http://www.ncbi.nlm.nih.gov/dbEST/index.html), or by BLAST searches using the BLAST-server
- a partial cDNA for human GPC4 was obtained by PCR on a human fetal kidney library (pKGP-PCR) .
- the sequence of this cDNA was used to design the primers for the RACE experiments and the isolation of cDNA for the complete coding sequence of human GPC4.
- the 5 ' -RACE and 3 ' -RACE experiments were performed on a library of adaptor-ligated ds fetal brain cDNA, using the Marathon cDNA Amplification kit from Clontech (Palo Alto, CA) .
- the cDNAs were amplified through a two-step PCR protocol. The first PCR used a gene-specific primer (Table 3) and an anchor primer provided by the supplier.
- the pKGP- PCR probe (corresponding to residues 422-1497 of the GPC4 cDNA sequence shown in figure 2) and the Notl-Bglll fragment (residues 1-386) of the GPC4 cDNA were gel purified, 32 P-labelled and used to screen a human genomic BAC library (Research Genetics, Inc . , Huntsville, AL) . Two BACs, 35H9 and 151D8 were isolated with the PCR probe, and one BAC, 68G14, with the Notl-Bglll fragment.
- BAC 166D10 which contained exon-3 of GPC3
- BAC 36D20 which contained exon-2 of GPC3.
- Metaphase spreads were prepared from PHA- stimulated human peripheral blood lymphocytes cultured for 72 hours. Prior to FISH, slides were treated with RNAse A and pepsin as described (Wiegant et al . , 1991) . Human Cotl DNA (Life Technologies) was used as a competitor. Denaturation of the slides and probes, hybridization, and subsequent cytoche ical detection of the hybridization signals were performed as previously described (Vermeesch et al . , 1995). Chromosomes were counterstained with DAPI and the slides were mounted in Vectashield mounting medium (Vector Laboratories Inc, Burlingame, CA) . The signal was visualized by digital imaging microscopy using a cooled charge-coupled device camera (Photometries Ltd, Arlington, AZ) . Merging and pseudocoloring were performed using the Smart Capture software (Vysis, Stuttgart, Germany).
- Exon-intron boundaries were determined by cycle-sequencing of BAC DNA using gene specific primers. Alternatively, BAC DNA was subcloned in plasmids, verified for the presence of GPC4 exons (by PCR and Southern blotting) and subsequently sequenced.
- ATCC American Type Culture Collection
- BACs 35H9 and 68G14 were sequenced and used to construct the novel sequence-tags (STS) MVl, MV2 and MV3 (Table 5) .
- the PAC-library from P. de Jong was screened with 32 P-oligolabeled probes for MVl, exon-1 GPC4 , exon-2 GPC4 and exon- 8 GPC3. PAC content was verified by PCR. STS ' s for GPC4 exons are described in Table 5, STS ' s SWXD1698, SWXD1165 and sWXD2342 have been described by others (see The Genome Database http : //www.gdb. org) .
- the reaction cycles for STS ' s MVl, MV2 and MV3 were: 94 °C for 30 sec, 55°C for 30 sec, 72° for 30 sec, for 35 cycles. Cycling was preceded by a 150 sec incubation at 94 °C.
- the membranes for the Northern blots were obtained from Clontech. Hybridization was performed for two hours at 68 °C, using Expresshyb solution (Clontech) according to the manufacturer's specifications.
- the probe was either a 32 P-oligolabeled Notl-Bglll fragment from one of the 5 'RACE clones (corresponding to residues 1-386 of the sequence shown in figure 2) , or a 32 P-oligolabeled BamHI-BamHI fragment from the composite cDNA sequence constructed in pREP4 (corresponding to residues 1148-2291 of the sequence shown in figure 2) .
- Dehybridisation included washing at room temperature for 30 min with 2.0% SSC, 0.05% SDS and a high stringency wash for 30 min at 0.1% SSC, 0.1% SDS and 65°C.
- Genomic DNA was obtained from one newly identified patient, counseled at the Center for Human Genetics (CME) of the University of Leuven (with informed consent from the parents); from the lymphoblastoid cell lines AG0817, AG0857, AG0893, AG0946, AG0969, and FY0367 (database IDs) from the European Collection of Cell Cultures (ECACC) ; and from the fibroblastic cell lines GM13034, GM3884, GM0097 (ATCC), all established from patients with SGBS. All patient DNAs were analyzed by PCR. The reaction cycles were: 94 °C for 30 sec, annealing temperature for 30 sec, 72°C for 30 sec, for 35 cycles. Cycling was preceded by a 2.5 minute incubation at 94°.
- reaction products were analyzed by electrophoresis in 2% agarose gels or, alternatively, were analyzed for single-strand conformation polymorphisms (SSCP) in non-denaturing polyacrylamide gels as described previously (Matthijs et al . , 1997) .
- PCR products with variant SSCs and controls were sequenced, either directly after gel purification or after T/A cloning in pCR2.1 (Invitrogen) . In the latter case, several independent clones from independent amplifications were characterized by Dye Primer Cycle Sequencing.
- a Notl-EcoRI fragment from a 5' RACE clone, a EcoRI-Pstl fragment from pKGP, and a Pstl- BamHI fragment from a 3 ' -RACE clone were ligated together in pBluescript.
- a Notl-Notl fragment containing GPC4 was isolated from this construct and ligated in pCDNAIII and pREP4 , yielding respectively glyp4-pcDNAIII and glyp4- pREP4.
- Namalwa cells (ATCC CRL 1432) were routinely grown in DMEF12 medium supplemented with 10% FCS and
- the cells were prewashed with Ca- and Mg-free PBS and incubated for 10 min at 4°C (10 7 cells in 1 ml Ca/Mg free PBS) with 30 ⁇ g glyp4-pREP4 plasmid before electroporation at 240 V and 960 ⁇ F (Gene Pulser, Biorad) . Selection was started 48 h later with 250 ⁇ g/ml of hygromycin B. Stable transfection was achieved after 12 days.
- 26 pcDNAIII selected in media containing 400 ⁇ g/ml of G418, and panned on 10E4 antibody.
- AATAAA sequence potential polyadenylation signal
- the protein sequence starts and terminates with hydrophobic signal peptide-like sequences. It contains three serine-glycine dipeptide sequences. All three Ser- Gly dipeptide sequences occur towards the C-terminus of the protein, and two of these form part of a direct Ser- Gly repeat sequence. These Ser-Gly sequences are flanked, both upstream and downstream, by acidic amino acids (D/E) , reproducing a motif that has been reported to promote the assembly of heparan sulfate in proteoglycans (Zhang et al . , 1995). Because of the presence of three Ser-Gly repeats, glypican-4 would be predicted to have up to three heparan sulfate chains implanted on its core protein.
- D/E acidic amino acids
- the acidic residue downstream of the Ser-Gly repeat occurs within the sequence CEYQQC, and may reproduce a motif (a small acidic loop supported by a disulfide bond) that is shared by most glypicans (except glypican-2) .
- This loop follows the SG repeats in the glypicans -1, -4 and -6, but interrupts or precedes the SG repeats in the glypicans -3 and -5.
- both probes corresponding either to residues 1-386, or residues 1148- 2291 of the GPC4 sequence were detecting two messages, one of 2.9 and one of 4.3 kb.
- the messages were expressed, in several, but not all, of the human fetal and adult tissues tested (see figure 11) .
- the origin of these two bands is not known, but could be due to the alternative usage of multiple polyadenylation signals, alternative splicing or, less likely, cross-hybridization with messages for other (possibly yet to be identified) members of the glypican gene family.
- fetal tissues the messages were expressed in brain, kidney and lung; but barely detectable in liver.
- the glypican-4 insert was subcloned in the pREP4 episomal expression vector and transfected in Namalwa cells.
- the Namalwa cells used for these experiments had previously been shown to express little endogenous heparan sulfate, but to support the synthesis of large amounts of heparan sulfate when transfected with cDNAs (cloned in pREP4) that code for syndecans or glypican-1.
- BAC 35H9, BAC 151D8, and BAC 68G12 Three BACs were identified for GPC4 : BAC 35H9, BAC 151D8, and BAC 68G12. BACs 35H9 and 151D8 contained exons 2 to 9 of GPC4 , while BAC 68G12 contained exon-1 of GPC4.
- FISH performed on metaphase chromosomes, localized all BACs for GPC4 to Xq26 (figure 12) . Since GPC3 had also been localized to chromosome band Xq26 (Pilia et al .
- GPC3 (closely related to GPC5) and GPC4 (closely related to GPC6) probably mapped in proximity of one another on Xq26, mimicking the clustering of the GPC5 and GPC6 genes on chromosome 13q32 (see example 1) .
- SGBS Simpson-Golabi-Behmel
- FIG. 13 shows the BAC/PAC contig containing the entire GPC4 gene and linking both GPC3 and GPC4. This contig indicates that both glypicans form a tandem array with exon-1 and the promotor region of GPC4 lying adjacent to the last exon of GPC3.
- the GPC4 gene exon/intron structure is schematically shown in Table 7.
- Genomic DNA was obtained from one newly identified patient, counseled at the Center for Human Genetics (CME) of the University of Leuven (with informed consent from the parents) ; from the lymphoblastoid cell lines AG0817, AG0857, AG0893, AG0946, AG0969, and FY0367 (database IDs) from the
- ECACC European Collection of Cell Cultures
- ATCC fibroblastic cell lines GM13034, GM3884, GM0097
- All patient DNAs were analyzed by PCR.
- the reaction cycles were: 94°C for 30 sec, annealing temperature for 30 sec, 72 °C for 30 sec, for 35 cycles. Cycling was preceded by a 2.5 minute incubation at 94°. Primers and annealing temperatures are given in Table 8.
- the reaction products were analyzed by electrophoresis in 2% agarose gels.
- PCR primer pairs were designed for amplification of all exons of GPC4 (including exon/intron boundaries, Table 11) and the corresponding PCR products were analyzed for single- strand conformation polymorphisms (SSCP) in non- denaturing polyacrylamide gels as described previously (Matthijs et al . , 1997). PCR products with variant SSCs and controls were either directly sequenced after gel purification or T/A cloned in pCR2.1 (Invitrogen) . Several independent clones from independent amplifications were characterized by Dye Primer Cycle Sequencing.
- SSCP single- strand conformation polymorphisms
- W 296 corresponds to one of the residues that are strictly conserved in all glypicans identified so far.
- Deletion of one T nucleotide (del T875) leading to a frame shift mutation and termination, was the basis for the variant SSC of exon 3 in a third patient (b) .
- SSCA of the GPC4 exons revealed polymorphisms for the exons 7 and 8, in one and the same patient. Sequencing of the PCR product of exon-7 in this patient identified a G>T mutation leading to a substitution of D 391 by E in glypican-4 (c) .
- GPC-4 Ex-1 5 ' -ggggCATCgTTCTTgTTgAA PR07-44 F-E (AS)
- GPC-4 Ex-2 5 ' -TCATCAAACTTCTTgTAACg PR10-26 F-E (AS)
- GPC-4 Ex-3 5 ' -AAGTGGTACTGGGAGTTCAC PR10-50
- F-E (AS) GPC-4 Ex-4: 5 ' -CTCCAGCAAGCACAAATATG PR06-40
- F-E (AS) GPC-4 Ex-5: 5 ' -CTTCTgAgACACTTgAACAC PR06-41
- GPC-4 Ex-6 5 ' -CCAgTCggTCCAAACTAgTg PR09-11
- GPC-4 Ex-8 5 ' -AgTCCACgTCgTTCCCATTg PR09-10
- F-E (AS) GPC-4 Ex-9: 5 ' -CTCCACTCTCTCTg
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU24229/99A AU2422999A (en) | 1998-01-27 | 1999-01-20 | New members of the glypican gene family |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98200226.3 | 1998-01-27 | ||
EP98200226 | 1998-01-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999037764A2 true WO1999037764A2 (en) | 1999-07-29 |
WO1999037764A3 WO1999037764A3 (en) | 2000-02-03 |
Family
ID=8233325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1999/000329 WO1999037764A2 (en) | 1998-01-27 | 1999-01-20 | New members of the glypican gene family |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2422999A (en) |
WO (1) | WO1999037764A2 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003100429A2 (en) * | 2002-05-23 | 2003-12-04 | Sunnybrook And Women's College Health Sciences Centre | Diagnosis of hepatocellular carcinoma |
WO2004022595A1 (en) * | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE |
WO2006090136A2 (en) * | 2005-02-22 | 2006-08-31 | University Court Of The University Of Edinburgh | Genetic screening of animals |
US7303914B2 (en) * | 2003-01-30 | 2007-12-04 | Hongyang Wang | Monoclonal antibody against human hepatoma and use thereof |
US20120040452A1 (en) * | 2005-08-09 | 2012-02-16 | Oncotherapy Science, Inc. | Glypican-3 (gpc3)-derived tumor rejection antigenic peptides useful for hla-a2-positive patients and pharmaceutical comprising the same |
WO2016112423A1 (en) | 2015-01-16 | 2016-07-21 | Minomic International Ltd. | Glypican epitopes and uses thereof |
CN107338306A (en) * | 2017-07-23 | 2017-11-10 | 嘉兴允英医学检验有限公司 | A kind of kit for GPC1mRNA detection of expression |
WO2018038046A1 (en) * | 2016-08-22 | 2018-03-01 | 中外製薬株式会社 | Gene-modified non-human animal expressing human gpc3 polypeptide |
JP2020141702A (en) * | 2020-05-28 | 2020-09-10 | グリピー ホールディングス ピーティーワイ リミテッド | Glypican epitopes and uses thereof |
US11612149B2 (en) | 2015-07-10 | 2023-03-28 | Chugai Seiyaku Kabushiki Kaisha | Non-human animal having human CD3 gene substituted for endogenous CD3 gene |
-
1999
- 1999-01-20 WO PCT/EP1999/000329 patent/WO1999037764A2/en active Application Filing
- 1999-01-20 AU AU24229/99A patent/AU2422999A/en not_active Abandoned
Non-Patent Citations (6)
Title |
---|
DATABASE EMBL [Online] Accession Number AA001322, 20 July 1996 (1996-07-20) HILLIER L ET AL: "zh83a06.r1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 427858 5' similar to SW:GLYP_HUMAN P35052 GLYPICAN PRECURSOR" XP002109642 cited in the application * |
DATABASE EMBL [Online] Accession Number N87558, 25 July 1996 (1996-07-25) LIEW C C: "LL1806F Fetal heart, Lambda ZAP Express Homo sapiens cDNA clone LL1806 5' similar to K-glypican." XP002109643 cited in the application * |
FILMUS J ET AL: "Identification of a new membrane-bound heparan sulphate proteoglycan" BIOCHEMICAL JOURNAL., vol. 311, 15 October 1995 (1995-10-15), pages 561-565, XP002109639 LONDON, GB ISSN: 0264-6021 cited in the application * |
HUBER R ET AL: "Analysis of exon/intron structure and 400 kb of genomic sequence surrounding the 5'-promoter and 3'-terminal ends of the human glypican 3 (GPC3) gene" GENOMICS., vol. 45, no. 1, 1 October 1997 (1997-10-01), pages 48-58, XP002109641 SAN DIEGO., US ISSN: 0888-7543 cited in the application * |
VEUGELERS M ET AL: "Characterization of glypican-5 and chromosomal localization of human GPC5, a new member of the glypican gene family." GENOMICS., vol. 40, no. 1, 15 February 1997 (1997-02-15), pages 24-30, XP002109640 SAN DIEGO., US ISSN: 0888-7543 cited in the application * |
WATANABE K.: "K-glypican: a novel GPI-anhcored heparan sulfate proteoglycan that is highly expressed in developing brain and kidney." THE JOURNAL OF CELL BIOLOGY., vol. 130, no. 5, September 1995 (1995-09), pages 1207-1218, XP002109638 cited in the application * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003100429A3 (en) * | 2002-05-23 | 2004-02-19 | Sunnybrook & Womens College | Diagnosis of hepatocellular carcinoma |
WO2003100429A2 (en) * | 2002-05-23 | 2003-12-04 | Sunnybrook And Women's College Health Sciences Centre | Diagnosis of hepatocellular carcinoma |
US7883853B2 (en) | 2002-05-23 | 2011-02-08 | Sunnybrook Health Sciences Centre | Diagnosis of hepatocellular carcinoma |
WO2004022595A1 (en) * | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE |
US7303914B2 (en) * | 2003-01-30 | 2007-12-04 | Hongyang Wang | Monoclonal antibody against human hepatoma and use thereof |
WO2006090136A2 (en) * | 2005-02-22 | 2006-08-31 | University Court Of The University Of Edinburgh | Genetic screening of animals |
WO2006090136A3 (en) * | 2005-02-22 | 2007-02-15 | Univ Edinburgh | Genetic screening of animals |
US20120040452A1 (en) * | 2005-08-09 | 2012-02-16 | Oncotherapy Science, Inc. | Glypican-3 (gpc3)-derived tumor rejection antigenic peptides useful for hla-a2-positive patients and pharmaceutical comprising the same |
US8535942B2 (en) * | 2005-08-09 | 2013-09-17 | Oncotherapy Science, Inc. | Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLA-A2-positive patients and pharmaceutical comprising the same |
WO2016112423A1 (en) | 2015-01-16 | 2016-07-21 | Minomic International Ltd. | Glypican epitopes and uses thereof |
CN107531755A (en) * | 2015-01-16 | 2018-01-02 | 美侬米克国际有限公司 | Glypican epitope and application thereof |
JP2018504903A (en) * | 2015-01-16 | 2018-02-22 | ミノミック インターナショナル リミティド | Glypican epitopes and uses thereof |
CN107531755B (en) * | 2015-01-16 | 2022-02-25 | 美侬米克国际有限公司 | Phosphatidylglycoproteoglycan epitopes and uses thereof |
EP3245219A4 (en) * | 2015-01-16 | 2018-06-06 | Minomic International Ltd. | Glypican epitopes and uses thereof |
US11612149B2 (en) | 2015-07-10 | 2023-03-28 | Chugai Seiyaku Kabushiki Kaisha | Non-human animal having human CD3 gene substituted for endogenous CD3 gene |
JPWO2018038046A1 (en) * | 2016-08-22 | 2019-06-20 | 中外製薬株式会社 | Genetically modified non-human animal expressing human GPC3 polypeptide |
WO2018038046A1 (en) * | 2016-08-22 | 2018-03-01 | 中外製薬株式会社 | Gene-modified non-human animal expressing human gpc3 polypeptide |
US11793180B2 (en) * | 2016-08-22 | 2023-10-24 | Chugai Seiyaku Kabushiki Kaisha | Gene-modified mouse expressing human GPC3 polypeptide |
CN107338306A (en) * | 2017-07-23 | 2017-11-10 | 嘉兴允英医学检验有限公司 | A kind of kit for GPC1mRNA detection of expression |
JP2020141702A (en) * | 2020-05-28 | 2020-09-10 | グリピー ホールディングス ピーティーワイ リミテッド | Glypican epitopes and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
WO1999037764A3 (en) | 2000-02-03 |
AU2422999A (en) | 1999-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Veugelers et al. | GPC4, the gene for human K-Glypican, FlanksGPC3on Xq26: Deletion of theGPC3–GPC4Gene cluster in one family with Simpson–Golabi–Behmel syndrome | |
US6596488B2 (en) | Tumor suppressor gene | |
Ferrero et al. | The making of a leukocyte receptor: origin, genes and regulation of human CD38 and related molecules | |
CA2268771C (en) | Polymorphisms and new genes in the region of the human hemochromatosis gene | |
WO1999037764A2 (en) | New members of the glypican gene family | |
WO1997042314A1 (en) | Nucleic acid encoding spinocerebellar ataxia-2 and products related thereto | |
Larsen et al. | The WFDC1 gene encoding ps20 localizes to 16q24, a region of LOH in multiple cancers | |
WO1997023598A2 (en) | A long qt syndrome gene which encodes kvlqt1 and its association with mink | |
WO1998057982A2 (en) | Aib1, a steroid receptor co-activator | |
US20060275314A1 (en) | Transmembrane protein differentially expressed in cancer | |
US20060211033A1 (en) | Novel gene | |
EP1033404A1 (en) | New gene with down-regulated expression in metastatic human melanoma cells | |
Suzuki et al. | A novel gene in the chromosomal region for juvenile myoclonic epilepsy on 6p12 encodes a brain-specific lysosomal membrane protein | |
JP2004500077A (en) | NPHS2 gene involved in steroid-resistant nephrotic syndrome, protein encoded by the gene, and diagnostic and therapeutic uses thereof | |
WO1999003883A1 (en) | Compositions and methods based upon the tuberous sclerosis-1 (tsc1) gene and gene product | |
US7112419B2 (en) | Human hepatoma associated protein and the polynucleotide encoding said polypeptide | |
AU762987B2 (en) | Chondrosarcoma associated genes | |
US20040214990A1 (en) | Transmembrane protein differentially expressed in cancer | |
EP1038960A1 (en) | BSMAP, a surface protein expressed specifically in the brain | |
WO2004072268A2 (en) | Pkhdl1, a homolog of the autosomal recessive kidney disease gene | |
WO1993024628A9 (en) | SEQUENCE OF HUMAN DOPAMINE TRANSPORTER cDNA | |
JP2002369696A (en) | Treatment and diagnosis of disease of kiaa0172 gene and utilization of the same gene to drug | |
US20030104472A1 (en) | Antibody specifically binding human pinch protein homolog | |
WO2001032861A1 (en) | Tumour suppressor genes from chromosome 16 | |
WO1999043695A1 (en) | Best's macular dystrophy gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
NENP | Non-entry into the national phase in: |
Ref country code: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase in: |
Ref country code: CA |